Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
- 360 Downloads
Objectives:The aim was to evaluate the association between serum vitamin D (25-hydroxyvitamin D) level and risk of prostate cancer.
Methods:The nested case–control study was based on a 13-year follow-up of about 19,000 middle-aged men who attended the first screening visit within the Helsinki Heart Study and were free of clinically verified prostate cancer at baseline. Through record linkage with the files of the Finnish Cancer Registry, 149 prostate cancer cases were identified in the cohort. They were matched (1:4) to probability density sampled controls for age, time of sample retrieval, and residence. Serum levels of 25-hydroxyvitamin D (25-VD) at entry were measured for cases and controls. The relative risks of prostate cancer were derived using conditional logistic regression analysis.
Results:Prostate cancer risk, analyzed by quartiles of the 25-VD levels, was inversely related to 25-VD. Men with 25-VD concentration below the median had an adjusted relative risk (OR) of 1.7 compared to men with 25-VD level above the median. The prostate cancer risk was highest among younger men (<52 years) at entry and low serum 25-VD (OR 3.1 nonadjusted and 3.5 adjusted). Among those younger men (<52 years), low 25-VD entailed a higher risk of non-localized cancers (OR 6.3). The mean age at diagnosis of the patients with 25-VD concentration above the median was 1.8 years higher than that of patients with vitamin D below the median (63.1 vs 61.3 years).
Conclusions: We conclude that low levels of 25-VD associated with an increased risk for subsequent earlier exposure and more aggressive development of prostate cancer, especially before the andropause.
Unable to display preview. Download preview PDF.
- 1.Gross C, Peehl D, Feldman D (1997) Vitamin D and prostate cancer. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego, CA: Academic Press, pp. 1125–39.Google Scholar
- 2.Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307–1311.Google Scholar
- 3.Hanchette CL, Schwartz GG (1992) Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861–2869.Google Scholar
- 4.Corder EH, Guess HA, Hulka BS, et al. (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2: 467–472.Google Scholar
- 5.Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6: 235–239.Google Scholar
- 6.Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5: 121–126.Google Scholar
- 7.Nomura AMY, Stemmermann GN, Lee J, et al. (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9: 425–432.Google Scholar
- 8.Bikle DD (1992) Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocrinol Rev 13: 765–784.Google Scholar
- 9.Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25–dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952–1960.Google Scholar
- 10.Peehl DM, Skowronski RJ, Leung GK, et al. (1994) Antiprolif-erative e.ects of 1,25–dihydroxyvitamin D3 on primary cultures of human prostatic cancer cells. Cancer Res 54: 805–810.Google Scholar
- 11.Kivineva M, BlaÈuer M, SyvaÈlaÈ H, et al. (1998) Localization of 1,25–dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 66: 121–127.Google Scholar
- 12.Schwarz GG, Oeler TA, Uskovic MR, Bahnson RR (1994) Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 14: 1077–1082.Google Scholar
- 13.Schwartz GG, Wang M-H, Zhang RK, et al. (1997) 1a,25–dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6: 727–732.Google Scholar
- 14.Lucia MS, Anzano MA, Slayter MV, et al. (1995) Chemopreven-tive activity of tamoxifen, N-(4–hydroxyphenyl)retinamide, and the vitamin D analogue Ro24–5531 for androgen-promoted carcino-mas of the rat seminal vesicle and prostate. Cancer Res 55: 5621–5627.Google Scholar
- 15.Hughes MR, Baylink DJ, Jones PG, et al. (1976) Radioligand receptor assay for 25–hydroxyvitamin D and 1a,25–dihydroxyvita-min D2/D3. J Clin Invest 58: 61–70.Google Scholar
- 16.Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthetize 1,25–dihydroxyvitamin D3 from 25–hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7: 391–395.Google Scholar
- 17.Frick MH, Elo O, Haapa K, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245.Google Scholar
- 18.Fraser DR (1995) Fat-soluble vitamins, vitamin D. Lancet 345: 104–107.Google Scholar
- 19.Lissner D, Mason RS, Posen S (1981) Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem 27: 773–774.Google Scholar
- 20.Lund BC, Bever-Stille KA, Perry PJ (1999) Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 19: 951–956.Google Scholar
- 21.Ahonen MH, Zhuang Y-H, Aine R, Ylikomi T, Tuohimaa P (2000) Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 86: 40–46.Google Scholar
- 22.Reichel H, Koe.er HP, Norman AW (1989) The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980–981.Google Scholar
- 23.Chen SE, Wietrzyk J, Chrobak A, et al. (2000) The in vitro evaluation of 25–hydroxyvitamin D3 and 19–nor-1–alpha,25–dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 6: 901–908.Google Scholar
- 24.Malabanan A, Veronikis IE, Holick MF (1998) Redefining vitamin D insuffciency. Lancet 351: 805–806.Google Scholar